Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.62 |
| ▸ | MPC2 | O95563 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL501421 | 0.99 | PPARG (0.61) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL877848 | 0.92 | PPARG (0.65) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL4622433 | 0.85 | PPARG (0.57) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6896704 | 0.81 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL4177074 | 0.80 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6896700 | 0.79 | PPARG (0.86) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL7836834 | 0.78 | FFAR1 (0.56) | PPARGFFAR1PPARA | |
| SCHEMBL4857396 | 0.77 | PPARG (0.56) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL5319250 | 0.77 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL2906120 | 0.77 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670744-B9 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACI DS AND ANALOGS | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-05 | — | — | EP | disclosed |
| EP-1670744-B1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACI DS AND ANALOGS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-04 | — | — | EP | disclosed |
| EP-1915999-A1 | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof. | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1715887-B1 | N-TERMINALLY MONOPEGYLATED HUMAN GROWTH HORMONE CONJUGATES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | PHARMACIA CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1789092-A2 | GLYCEROL BRANCHED POLYETHYLENE GLYCOL HUMAN GROWTH HORMONE CONJUGATES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE THEREOF | Pharmacia & Upjohn Company LLC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024953-A2 | GLYCEROL BRANCHED POLYETHYLENE GLYCOL HUMAN GROWTH HORMONE CONJUGATES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE THEREOF | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20040142870-A1 | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142870-A1 | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof | GHRHR, PTMS, GHITM | PPARG 1971/4885MPC2 1958/4885CYP2C8 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.